Resumen de Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab
C. Panciroli, G. Lucente, Laura Vidal, Enric Carcereny Costa, Vanessa Quiroga, J. C. Pardo, Margarita Romeo Marín, Anna Estival González, José Luis Manzano Mozo, B. Pardo, J.M. Velarde, A. M. Esteve, D. Lopez, A. Mañes, V. Tuset, Salvador Villà Freixa, Carmen Balaña Quintero
Purpose We performed a cross-sectional study of neurocognitive function in non-brain cancer patients treated with long-term bevacizumab.
Methods/patients From 2015 to 2017, we included patients with different types of cancer treated with bevacizumab with or without chemotherapy (BEV; N = 20) or only chemotherapy (ChT; N = 19) for at least 34 weeks, patients who received non-brain radiotherapy (RxT; N = 19), and healthy controls (HC; N = 19) were assessed once at week 34 of treatment (BEV and ChT) or at completion of radiotherapy. Neurocognition was evaluated with the Hopkins Verbal Learning Test-Revised (HVLT-R) total and delayed recall, the Trail Making Test A and B, and the Controlled Oral Word Association Test in the four groups. Non-parametric tests were used to assess differences between groups.
Results The BEV, ChT, and RxT groups scored significantly lower than the HC group on all tests and especially on the HVLT-R total recall. In no case were the mean scores of the BEV group significantly lower than those of the ChT or RxT groups.
Conclusions Neurocognitive impairment was seen even in patients treated with local non-brain radiotherapy. Treatment with bevacizumab for a long period of time does not seem to worsen neurocognitive function to a greater extent than chemotherapy.
